sintilimab Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (2)

Phase 1 (1)
Phase 2 (1)

Interventional (2)

Innovent Biologics (Suzhou) Co. Ltd. (1)
Second Affiliated Hospital, School of Medicine, Zhejiang University (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/hadstroke

I am/have/hadsmall cell lung cancer

I am/have/hadtransient ischemic attack

I am/have/hadcancer

I am/have/hadblood test

I am/have/hadangina pectoris

I am/have/hadlung cancer

I am/have/hadmyocardial infarction

I am/have/hadnon-small cell lung cancer

I am/have/hadmental illness

I am/have/hadtuberculosis

I am/have/hadblood pregnancy test

I am/have/hadadjuvant therapy

I am/have/hadhepatitis

I am/have/haddiabetes

I am/have/hadunstable angina

I am/have/hadliver disease

I am/have/hadinterstitial lung disease

I am/have/hadneutrophil count

I am/have/hadproteinuria

added new label for I am/have/had

more

I am looking for

I am looking forpemetrexed

I am looking forsintilimab

I am looking forpaclitaxel

I am looking forcarboplatin

I am looking forgranulocyte colony stimulating factor

I am looking forg-csf

I am looking forcolony stimulating factor

added new label for I am looking for

more

Advanced Filters

Loading...

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC neoSCORE

This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.

pemetrexed

sintilimab

stroke

small cell lung cancer

transient ischemic attack

0 views
19 Feb, 2024

Ib Study of the Efficacy and Safety of IBI310 Combined With Sintilimab in Advanced Hepatocellular Carcinoma

An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.